375 related articles for article (PubMed ID: 21937983)
1. Alzheimer's therapeutics: translation of preclinical science to clinical drug development.
Savonenko AV; Melnikova T; Hiatt A; Li T; Worley PF; Troncoso JC; Wong PC; Price DL
Neuropsychopharmacology; 2012 Jan; 37(1):261-77. PubMed ID: 21937983
[TBL] [Abstract][Full Text] [Related]
2. Meeting report of the annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease research.
Sasner M; Territo PR; Sukoff Rizzo SJ
Alzheimers Dement; 2023 Nov; 19(11):5284-5288. PubMed ID: 37070936
[TBL] [Abstract][Full Text] [Related]
3. Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?
Banik A; Brown RE; Bamburg J; Lahiri DK; Khurana D; Friedland RP; Chen W; Ding Y; Mudher A; Padjen AL; Mukaetova-Ladinska E; Ihara M; Srivastava S; Padma Srivastava MV; Masters CL; Kalaria RN; Anand A
J Alzheimers Dis; 2015; 47(4):815-43. PubMed ID: 26401762
[TBL] [Abstract][Full Text] [Related]
4. The evolution of preclinical Alzheimer's disease: implications for prevention trials.
Sperling R; Mormino E; Johnson K
Neuron; 2014 Nov; 84(3):608-22. PubMed ID: 25442939
[TBL] [Abstract][Full Text] [Related]
5. Lost in Translation? Finding Our Way To Effective Alzheimer's Disease Therapies.
Quinn JF
J Alzheimers Dis; 2018; 64(s1):S33-S39. PubMed ID: 29758942
[TBL] [Abstract][Full Text] [Related]
6. Discovery of notch-sparing gamma-secretase inhibitors.
Augelli-Szafran CE; Wei HX; Lu D; Zhang J; Gu Y; Yang T; Osenkowski P; Ye W; Wolfe MS
Curr Alzheimer Res; 2010 May; 7(3):207-9. PubMed ID: 20088802
[TBL] [Abstract][Full Text] [Related]
7. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.
Barten DM; Meredith JE; Zaczek R; Houston JG; Albright CF
Drugs R D; 2006; 7(2):87-97. PubMed ID: 16542055
[TBL] [Abstract][Full Text] [Related]
8. Progress in the development of beta-secretase inhibitors for Alzheimer's disease.
Albert JS
Prog Med Chem; 2009; 48():133-61. PubMed ID: 21544959
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies.
Evin G; Sernee MF; Masters CL
CNS Drugs; 2006; 20(5):351-72. PubMed ID: 16696577
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Alzheimer's disease therapeutics.
Rafii MS
J Alzheimers Dis; 2014; 42 Suppl 4():S545-9. PubMed ID: 25079804
[TBL] [Abstract][Full Text] [Related]
11. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
Harrison T; Churcher I; Beher D
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
[TBL] [Abstract][Full Text] [Related]
12. Resolving controversies on the path to Alzheimer's therapeutics.
Selkoe DJ
Nat Med; 2011 Sep; 17(9):1060-5. PubMed ID: 21900936
[TBL] [Abstract][Full Text] [Related]
13. Novel approaches to models of Alzheimer's disease pathology for drug screening and development.
Shaughnessy L; Chamblin B; McMahon L; Nair A; Thomas MB; Wakefield J; Koentgen F; Ramabhadran R
J Mol Neurosci; 2004; 24(1):23-32. PubMed ID: 15314246
[TBL] [Abstract][Full Text] [Related]
14. [Toward Preclinical Trials for Alzheimer's Disease].
Miyagawa T; Iwatsubo T
Brain Nerve; 2017 Jul; 69(7):711-722. PubMed ID: 28739984
[TBL] [Abstract][Full Text] [Related]
15. Biaryl scaffold-focused virtual screening for anti-aggregatory and neuroprotective effects in Alzheimer's disease.
Khalid S; Zahid MA; Ali H; Kim YS; Khan S
BMC Neurosci; 2018 Nov; 19(1):74. PubMed ID: 30424732
[TBL] [Abstract][Full Text] [Related]
16. Animal models of Alzheimer's disease and drug development.
Laurijssens B; Aujard F; Rahman A
Drug Discov Today Technol; 2013 Sep; 10(3):e319-27. PubMed ID: 24050129
[TBL] [Abstract][Full Text] [Related]
17. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacology of Alzheimer's disease: where do we go from here?].
Sellal F; Nieoullon A; Michel G; Michel BF; Lacomblez L; Geerts H; Delini-Stula A; Bentué-Ferrer D; Bordet R; Allain H
Therapie; 2005; 60(2):89-107. PubMed ID: 15969312
[TBL] [Abstract][Full Text] [Related]
19. Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease.
Schneider LS
Alzheimers Dement; 2014 Mar; 10(2):247-50. PubMed ID: 24698029
[TBL] [Abstract][Full Text] [Related]
20. In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease.
Semighini EP
Chem Biol Drug Des; 2015 Sep; 86(3):284-90. PubMed ID: 25476252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
